Colossal targets 2030 for its first mammoth calves as elephant research raises questions for cancer biology
Ben Lamm told TIME’s Alice Park that a defense against damaged cells became an obstacle in the lab. Its value to medicine is still an open question.
An elephant’s ability to dispose of damaged cells is one reason cancer researchers study the animal. For Colossal Biosciences, that same defense became a problem. Cells the company wanted to keep alive for its woolly mammoth project kept shutting down, founder and CEO Ben Lamm told TIME senior health correspondent Alice Park. Understanding why they stopped growing became a research question in its own right, years before the company expects to see a calf.
“We’ve now moved the timeline to 2030,” Lamm said of the first calves, which Colossal had initially targeted for 2028. Speaking remotely at the Nov. 17 Main Stage session in Las Vegas, he put the mammoth team at about 40 people. Park asked what a project devoted to bringing back traits of an extinct animal could reasonably promise people who treat disease. Lamm’s strongest example concerned a problem his researchers had actually encountered. His predictions about cancer treatment and healthier aging were considerably further out.
What an elephant cell can tell a cancer researcher
Large animals pose a puzzle for cancer biology. An elephant has many more cells than a person and can live for decades. That gives damaged cells opportunities to accumulate over a lifetime, yet the animal appears to have a lower cancer mortality rate than its size might suggest. Researchers were investigating that discrepancy well before Colossal began its mammoth project.
A 2015 JAMA study examined records that included 644 elephant deaths and also compared the responses of elephant and human cells to DNA damage. The investigators found evidence of extra copies of a tumor-suppressor gene in elephants and a stronger tendency for damaged elephant cells to undergo programmed death. The death records and laboratory experiments answer different questions. One estimates how often cancer was implicated in recorded deaths. The other offers a possible biological explanation that researchers could test.
Lamm described the problem from the opposite direction. His team needed healthy elephant cells that could keep growing as scientists studied them. A strong response to damage made those cells difficult to work with. Yet disabling a protective response at the expense of the animal would defeat the purpose of the project, he said. The researchers had to consider both the viability of their cells in the lab and the consequences for an animal that might eventually develop from their work.
For a cancer researcher, that tension gives the experiment a more precise objective than a hunt for a cure in ancient DNA. When does a cell stop dividing, and what distinguishes a protective response from one that prevents healthy tissue from developing? Lamm identified cellular signaling and repair among the areas he would watch first. He offered no candidate drug, patient study or clinical timetable. Asked about the company’s role, he told Park, “we do not do any work on humans or nonhuman primates at Colossal.” He said other organizations can license its technologies.
The choice concealed in the word mammoth
Park returned to a question with consequences for how anyone will judge the 2030 target. If the starting point is a living Asian elephant and researchers choose traits associated with an extinct animal, what would make the resulting calf a woolly mammoth? The company’s project description calls its objective a cold-resistant elephant with the mammoth’s core biological traits. That formulation leaves room for disagreement about what a successful birth would establish.
Lamm said Colossal has 104 mammoth genomes spanning roughly 1.3 million years. In his account, the animals varied considerably over that interval. He argued that selecting traits shared across those generations makes more sense than treating any one animal as the definitive mammoth. He also invoked the ecological work an animal might perform in a cold environment. A calf’s appearance would be visible at birth. Its ability to thrive and perform that ecological role would take much longer to establish.
Conservation scientists have a term for this distinction. The International Union for Conservation of Nature’s Species Survival Commission uses the word proxy in its guiding principles for projects seeking a conservation benefit from recreating traits of extinct species. That vocabulary matters for healthcare audiences as well. A model can be useful even when it reproduces only selected features of what scientists hope to understand. The limit comes when a result about those features is treated as evidence about the entire organism.
Lamm gave Park a concrete instance in which fidelity to an extinct animal took second place to welfare. In Colossal’s wolf project, he said, the team chose an alternative route to a coat color because it saw evidence that the variant it had considered could carry health risks. He described the decision as a deliberate trade. Two animals could look alike while the underlying choices, and the risks borne by the animals, differed. Park pressed him on how much anyone can know about the consequences of altering one trait in a genome whose parts interact.
A precedent from diabetes and a limit in the delivery room
Lamm’s example of a medical payoff from studying an unusual animal came from outside his company. Research on a peptide in the Gila monster led to exenatide, a diabetes drug. The Department of Veterans Affairs’ research account traces the discovery to a VA investigator and notes that the FDA approved the synthetic version for medical use in 2005. It is a specific instance in which preserving and studying living species has value for medicine, even when nobody can predict which species will matter.
The example also sets a demanding standard for Colossal’s own ambitions. In the Gila monster story, one can name the molecule, the medicine and the condition it treats. In the elephant work, one can name an unusual cellular behavior and explain why it interests investigators. Getting from one kind of evidence to the other will require researchers willing to pursue a specific medical question, including the possibility that an observation in another species has little therapeutic value in people.
Park closed by asking Lamm which animal he would most like to see return. He chose Steller’s sea cow, an extinct marine mammal related to manatees and dugongs, and said it was a personal wish rather than a company project. The distinction brought the conversation back to the 2030 target. Even with a genome in hand, someone still has to account for how a large mammal will be carried and born. In Lamm’s telling, the biology of a pregnancy may set the pace long after the computational work is done.